FidoCure^® Veterinary Team Blog

We are excited to share an inspiring and insightful episode of "The Veterinary Optimist" podcast, featuring our very own Christina Lopes, CEO and Co-Founder of The One Health Company. In this special episode, Christina opens up about her journey, from her father’s battle with cancer to the loss of several beloved family dogs, and how these experiences fueled her passion for revolutionizing cancer treatment for pets.

Christina also delves into her background working with marginalized communities, which inspired her to focus on helping voiceless beings and ultimately led her to the veterinary field. Under her leadership, FidoCure has made remarkable strides, expanding into over 1,350 veterinary clinics and treating more than 5,000 dogs with innovative AI and genomic sequencing technologies.

We invite you to listen to Christina's story and learn more about our mission to improve the lives of dogs and their families with cancer. Tune in to the podcast on Apple Podcasts, and don’t forget to check out the full transcription of the episode below.

Thank you for being a part of the FidoCure community and supporting our mission to help over 1 million dogs live healthier, happier lives--and ultimately fight cancer on both ends of the leash.

A recent article in The New York Times, titled, "How science went to the dogs (and cats)," highlights the remarkable evolution of companion animal research over the past two decades. Once dismissed as trivial subjects, pets are now at the forefront of scientific inquiry, with researchers around the world delving deep into the bodies and minds of cats and dogs.

Explore the history and impact of small molecules in this fascinating discussion. FidoCure’s Chief Medical Officer, Dr. Gerry Post interviews Dr. Cheryl London about their application in canine cancer treatment.

Dr. Cheryl London is a world-renowned expert in veterinary oncology and targeted cancer therapies at Tufts University. Her pioneering work began in 2000 when she collaborated with SUGEN to develop Palladia, one of the first targeted small molecule drugs approved for veterinary use, treating canine mast cell tumors driven by KIT mutations. 

We are thrilled to share with you an incredible milestone in our journey to revolutionize canine cancer treatment. Thanks to your unwavering support and dedication, we have now enrolled over 5,000 dogs in the FidoCure platform! This achievement is a testament to the trust you have placed in our innovative approach and the positive impact we are making together in the lives of dogs and their families.

FidoCure by the One Health Company and Stanford University Research Shared at AACR 2024 

Our study in Nature's Scientific Reports was the 17th most downloaded cancer paper in 2023!

Revolutionizing Veterinary Oncology: Precision Medicine Paves the Way for Personalized Cancer Treatment in Dogs

We would like to express our heartfelt gratitude to our veterinary community as we come to the close of the year. Together, we have made a tremendous impact by enabling precision medicine to nearly 5,000 pet dogs battling cancer. 

FOR IMMEDIATE RELEASE

Precision Medicine Tools Offer Veterinarians New Hope for Understanding Deadly Dog
Cancer